Press Releases

Press Releases

Date Title
March 31, 2020
UNITY Biotechnology Completes Enrollment in Phase 1b Study of UBX0101
– Topline 12- and 24-week results expected in 2H 2020 – SAN FRANCISCO , March 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced updates
March 30, 2020
UNITY Biotechnology Announces Start of New CEO and New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif. , March 30, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. today announced that Anirvan Ghosh , Ph.D., has officially joined the company as Chief Executive Officer. As previously announced, Dr. Ghosh is a renowned scientist and drug development leader who joins UNITY
March 11, 2020
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results
SOUTH SAN FRANCISCO, Calif. , March 11, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the fourth quarter and full
March 3, 2020
UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2019 Financial Results
SAN FRANCISCO , March 03, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the fourth quarter and
March 2, 2020
UNITY Biotechnology Appoints Anirvan Ghosh, Ph.D. as Chief Executive Officer
– Renowned Scientist and Drug Developer Joins UNITY’s Mission to Extend Healthspan  – – Succeeds Keith Leonard Who Will Continue as Chairman – SAN FRANCISCO , March 02, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology today announced the appointment of Anirvan Ghosh , Ph.D., as CEO and member of the
February 25, 2020
UNITY Biotechnology Provides Pipeline and Business Updates
– Phase 2 study of UBX0101 in patients with osteoarthritis has completed enrollment – – Topline 12- and 24-week results now expected in 2H 2020 – – First patient dosed in phase 1b study to explore higher dose and repeat doses – – First-in-human study initiation for ophthalmology program expected in
February 24, 2020
UNITY Biotechnology, Inc. to Participate in the Cowen and Company 40th Annual Health Care Conference
SAN FRANCISCO , Feb. 24, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that Keith Leonard , chairman and chief executive officer,